Rallybio Q2 EPS $(0.37) Misses $(0.33) Estimate, Sales $299.00K
Portfolio Pulse from Benzinga Newsdesk
Rallybio (NASDAQ:RLYB) reported Q2 earnings per share (EPS) of $(0.37), missing the analyst consensus estimate of $(0.33) by 12.12%. This represents a 19.57% improvement over the $(0.46) per share loss from the same period last year. The company also reported $299.00 thousand in sales for the quarter.
August 08, 2024 | 12:40 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Rallybio reported Q2 EPS of $(0.37), missing the analyst estimate of $(0.33) by 12.12%. Despite the miss, the EPS shows a 19.57% improvement YoY. Sales were $299K for the quarter.
The EPS miss is likely to have a negative short-term impact on the stock price as it fell short of analyst expectations. However, the YoY improvement in EPS and reported sales may mitigate some of the negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100